ClinVar Miner

Submissions for variant NM_001378454.1(ALMS1):c.10774A>G (p.Thr3592Ala) (rs200467041)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000524071 SCV000618291 uncertain significance not provided 2021-08-02 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge
Invitae RCV000803220 SCV000943082 uncertain significance Alstrom syndrome 2020-10-31 criteria provided, single submitter clinical testing This sequence change replaces threonine with alanine at codon 3593 of the ALMS1 protein (p.Thr3593Ala). The threonine residue is moderately conserved and there is a small physicochemical difference between threonine and alanine. This variant is present in population databases (rs200467041, ExAC 0.2%). This variant has not been reported in the literature in individuals with ALMS1-related disease. ClinVar contains an entry for this variant (Variation ID: 449854). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: Tolerated; PolyPhen-2: Not Available; Align-GVGD: Class C0. The threonine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001255513 SCV001431950 uncertain significance not specified 2021-05-03 criteria provided, single submitter clinical testing Variant summary: ALMS1 c.10771A>G (p.Thr3591Ala) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00011 in 248704 control chromosomes, predominantly at a frequency of 0.0012 within the African or African-American subpopulation in the gnomAD database. This frequency is only slight lower than expected for a pathogenic variant in ALMS1 causing Alstrom Syndrome (0.0012 vs 0.0014), suggesting this variant may not associate the disease. To our knowledge, no occurrence of c.10771A>G in individuals affected with Alstrom Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Co-occurrences with other pathogenic variants have been reported (MYBPC3 c.1505G>A, p.Arg502Gln; TTN c.62134C>T, p.Gln20712X; MYBPC3 c.927-9G>A; internal testing), providing supporting evidence for a benign role. Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, citing the variant as uncertain significance (n=2) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as VUS-possibly benign..
Natera, Inc. RCV000803220 SCV001459598 likely benign Alstrom syndrome 2019-10-28 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.